Researchers at Weill Cornell Medicine and Cornell Duffield College of Engineering developed ultrasmall fluorescent core shell silica nanoparticles (C' dots) that demonstrate significant potential in treating aggressive prostate cancer.

In preclinical mouse studies, these nanoparticles caused tumor cells to self-destruct while transforming the tumor microenvironment from an immune-resistant 'cold' state to an immune-active 'hot' state.This dual-action approach enhances the effectiveness of immunotherapy, leading to complete remissions in multiple mice.

The nanoparticles, made from amorphous silica, trigger ferroptosis—a form of cell death via oxidative damage—by transporting iron ions into cancer cells.They also reprogram immune cells to attack tumors and disrupt metabolic processes within the tumor microenvironment.

Combining the nanoparticles with immunotherapy and CSF-1R blockade therapy achieved the highest survival rates, with five out of ten mice experiencing complete remissions.The study highlights a novel paradigm for cancer treatment, merging direct tumor cell destruction with immune system activation.

The next step is evaluating this approach in human clinical trials, with potential applications in personalized medicine and immunotherapy advancements.